Relmada Therapeutics Reports Positive Momentum in Q2 Earnings Call

Relmada Therapeutics reported positive momentum in its Q2 earnings call, with impressive Phase II results for NDV-01, strategic additions to its portfolio, and strong financial management. However, the company faced challenges with decreased cash reserves and reduced R&D spending, which may impact future developments. Despite these challenges, the company plans to initiate Phase III studies for NDV-01 and continue its focus on bladder cancer and compulsivity disorders.

Relmada Therapeutics, Inc. (Nasdaq: RLMD) delivered positive momentum in its Q2 2025 earnings call, highlighting impressive Phase II results for NDV-01, strategic additions to its portfolio, and strong financial management. The company reported a 91% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC) for NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel (Gem/Doce) [1]. This promising data, coupled with the company's plans to initiate Phase III studies for NDV-01, signals a potential breakthrough in the treatment of bladder cancer.

Relmada also announced its intention to launch a Phase 2 study for sepranolone, a first-in-class GABAA Modulating Steroid Antagonist (GAMSA), in the first half of 2026. Sepranolone is being developed for Prader-Willi syndrome (PWS), Tourette syndrome (TS), essential tremor, and other compulsivity-related disorders [1]. This strategic addition to the company's pipeline demonstrates its commitment to addressing significant unmet needs in both oncology and central nervous system conditions.

However, the company faced challenges with decreased cash reserves and reduced R&D spending. The net loss for the six months ended June 30, 2025, was $27.4 million or $0.86 per share, compared to $39.6 million or $1.31 per share for the same period in 2024 [1]. The company's cash, equivalents, and short-term investments stood at $20.6 million as of June 30, 2025, down from $44.9 million at year-end 2024 [1]. These financial challenges may impact future developments, but the company remains focused on its pipeline and strategic initiatives.

Relmada's conference call and webcast, scheduled for today at 4:30 PM ET, will provide further insights into the company's Q2 results and pipeline progress. Investors and financial professionals are encouraged to tune in to stay informed about the company's future trajectory [1].

References:
[1] https://www.morningstar.com/news/globe-newswire/9508544/relmada-therapeutics-reports-second-quarter-2025-financial-results-and-announces-ndv-01-6-month-follow-up-safety-and-efficacy-data-in-nmibc